Demonetisation, Swachh Bharat Abhiyan, Make in India, Digital India, Ayushmaan Bharat and implementation of GST have been the major highlights of the BJP-led government. The government also initiated policies and invited many foreign investors to boost exports. Ayushmaan Bharat is another recognised initiative and may have the potential to be a game changer in the industry. The government has also initiated scaling up the Jan-Aushadhi scheme across India to provide generic drugs to the masses at a low cost with easy accessibility. However, the momentum that it gained is slower than what was expected. Industry experts highlight the hits and misses of the present NDA government and share their expectations from the new administration. BY USHA SHARMA
‘We expect further fine tuning of the existing schemes and policies’
‘Hoping that the future of Indian Pharma is brighter than before’
‘I expect more bold initiatives on macro-economic front’
‘Funding for pharma companies might be a way to move forward’
‘There is a definite need to support SME upgradation’
‘We expect the new govt to reduce regulatory intervention’
- Advertisement -
Comments are closed.